NCI-2024-07203

A Phase 1, Open-label, Multicenter Study of ZW171 in Participants With Advanced or Metastatic Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), and Other Mesothelin Expressing Cancers

This is a Phase 1 research stydy designed to test a new experimental drug called ZW171 in people with certain types of advanced or metastatic cancers, including ovarian cancer, non-small cell lung cancer (NSCLC), and other cancers that have a protein called mesothelin on the surface of their tumor cells. Mesothelin is often found in high amounts in some cancers and is being targeted by ZW171 to help destroy cancer cells more precisely. The study is open-label, meaning doctors and patients know they’re getting ZW171, and it’s being carried out at multiple hospitals or cancer centers.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

Non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06523803

Clinical Trial Site: Sinai

To see all available clinical trials click here.